Drug Discovery

Hoth Therapeutics' Merveille.ai Achieves Breakthrough in Obesity Treatment with AI-Driven Therapeutic Candidate

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, is excited to announce a significant breakthrough by its sub...

 March 28, 2024 | News

TiumBio Initiates Phase 1b Trial for New Hemophilia Treatment TU7710

TiumBio Co., Ltd., a trailblazer in the biopharmaceutical landscape, dedicated to crafting groundbreaking therapies for rare and untreatabl...

 March 27, 2024 | News

DigmBio's Breakthrough Cancer Drug Clears Korean Regulatory Hurdle

BioDuro-Sundia's partner, DigmBio, a South Korean biotechnology company, announced its selective PARP1 inhibitor for the treatment of triple-negative breas...

 March 26, 2024 | News

Takeda Receives FDA Approval for ICLUSIG as a First-Line Treatment in Ph+ ALL

Takeda Receives FDA Approval for ICLUSIG as a First-Line Treatment in Ph+ ALL   Takeda Pharmaceutical Company Limited (TSE: 4502; NYSE: TAK) is plea...

 March 25, 2024 | News

AriBio Secures Exclusive $770M Deal for Alzheimer's Drug in China

AriBio Co., Ltd. (AriBio), announces signing of exclusive marketing rights for AR1001, an investigational drug for early Alzheimer’s disease, in Chin...

 March 25, 2024 | News

Vertex Pharmaceuticals Receives FDA Clearance for Innovative ADPKD Drug Trial

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) f...

 March 22, 2024 | News

Oscotec Inc. Gains FDA Orphan Drug Designation for Promising ITP Treatment Cevidoplenib

Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immun...

 March 22, 2024 | News

Antengene Advances ATG-022 in Phase II CLINCH Study for Solid Tumors in China and Australia,

Antengene Corporation Limited, a prominent global biopharmaceutical entity focused on the development and commercialization of pion...

 March 21, 2024 | News

Takeda Achieves Groundbreaking FDA Approval for ICLUSIG® in Treating Newly Diagnosed Ph+ ALL Patients

This approval marks a pioneering step in treating adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) ALL, offering a combination th...

 March 20, 2024 | News

Cognizant and NVIDIA Accelerate Drug Discovery with Generative AI

Cognizant (NASDAQ: CTSH) is advancing the application of generative AI (gen AI) technology with the NVIDIA BioNeMo platform to solve complex chal...

 March 20, 2024 | News

BioGeometry and Sanyou Bio Announce Pioneering Alliance to Accelerate AI-Powered Antibody Research

BioGeometry, a frontrunner in digital biology and AI-driven protein design, alongside Sanyou Bio, a leading force in the high-tech biotechnology sector, ha...

 March 19, 2024 | News

FDA Grants Fast Track Designation to ImmVira's MVR-T3011 IT for Advanced Head and Neck Cancer

ImmVira's groundbreaking oncolytic virus therapy, MVR-T3011 IT intratumoral injection, has been awarded Fast Track designation by the U.S. Food and Drug Ad...

 March 18, 2024 | News

Mirum Pharmaceuticals Announces FDA Approval of LIVMARLI for Cholestatic Pruritus in PFIC Patients

    Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leader in developing innovative treatments for rare liver diseases, has proudly announced the...

 March 14, 2024 | News

Sanyou Biopharmaceuticals Launches Groundbreaking Intelligent Innovative Biologics R&D Service Platform

Sanyou Biopharmaceutical Co., Ltd. is delighted to announce the official launch of the "Sanyou Intelligent Innovative Biologics R&D Service Platform," ...

 March 13, 2024 | News


Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close